Moomoo AIのまとめ
Tempus AI, Inc. reported robust financial results for Q3 2024, with total revenue increasing 33% year-over-year to $180.9 million. Genomics revenue grew 20% to $116.4 million, while Data and services revenue surged 64% to $64.5 million. The company performed approximately 69,000 oncology NGS tests during the quarter, up from 55,700 in Q3 2023.The company continued to invest heavily in research and development, with expenses increasing to $58 million compared to $47.4 million in Q3 2023. Operating expenses rose to $234.5 million from $180.8 million last year, primarily due to $21 million in stock-based compensation and increased personnel costs. Net loss widened to $75.8 million from $53.4 million in Q3 2023.Tempus strengthened its strategic position by announcing the acquisition of Ambry Genetics for $375 million in cash plus 4.8 million shares of Class A common stock. The company also expanded internationally through its joint venture with SoftBank in Japan, contributing $95.2 million to form SB Tempus. The company maintained a strong balance sheet with $388.9 million in cash and cash equivalents as of September 30, 2024.
Tempus AI, Inc. reported robust financial results for Q3 2024, with total revenue increasing 33% year-over-year to $180.9 million. Genomics revenue grew 20% to $116.4 million, while Data and services revenue surged 64% to $64.5 million. The company performed approximately 69,000 oncology NGS tests during the quarter, up from 55,700 in Q3 2023.The company continued to invest heavily in research and development, with expenses increasing to $58 million compared to $47.4 million in Q3 2023. Operating expenses rose to $234.5 million from $180.8 million last year, primarily due to $21 million in stock-based compensation and increased personnel costs. Net loss widened to $75.8 million from $53.4 million in Q3 2023.Tempus strengthened its strategic position by announcing the acquisition of Ambry Genetics for $375 million in cash plus 4.8 million shares of Class A common stock. The company also expanded internationally through its joint venture with SoftBank in Japan, contributing $95.2 million to form SB Tempus. The company maintained a strong balance sheet with $388.9 million in cash and cash equivalents as of September 30, 2024.
Tempus AI, Inc.は2024年第3四半期に堅調な財務結果を報告し、総売上高は前年同期比で33%増の$18090万に達した。ゲノミクスの売上高は20%増の$11640万、データ及びサービスの売上高は64%増の$6450万に急増した。会社はこの四半期に約69,000件の腫瘍NGS検査を実施し、前年同期の55,700件から増加した。会社は研究開発に多額の投資を続けており、費用は2023年第3四半期の$4740万から$5800万に増加した。営業費用は昨年の$18080万から$23450万に上昇し、主に$2100万の株式報酬と人件費の増加によるものだ。純損失は2023年第3四半期の$5340...すべて展開
Tempus AI, Inc.は2024年第3四半期に堅調な財務結果を報告し、総売上高は前年同期比で33%増の$18090万に達した。ゲノミクスの売上高は20%増の$11640万、データ及びサービスの売上高は64%増の$6450万に急増した。会社はこの四半期に約69,000件の腫瘍NGS検査を実施し、前年同期の55,700件から増加した。会社は研究開発に多額の投資を続けており、費用は2023年第3四半期の$4740万から$5800万に増加した。営業費用は昨年の$18080万から$23450万に上昇し、主に$2100万の株式報酬と人件費の増加によるものだ。純損失は2023年第3四半期の$5340万から$7580万に拡大した。Tempusは、$37500万の現金と480万株のClass A 普通株式でAmbry Geneticsの買収を発表し、戦略的地位を強化した。会社はまた、日本でのソフトバンクとの合弁事業を通じて国際的に拡大し、Sb Tempusを形成するために$9520万を貢献した。会社は2024年9月30日現在、$38890万の現金及び現金同等物を保持し、強固なバランスシートを維持している。
役に立った
役に立たない
コメント(0)
報告理由